secwatch.observer — SEC 8-K summary
======================================

Issuer:     Liquidia Corp (LQDA)
CIK:        0001819576
Form:       8-K
Filed at:   2023-08-10T23:59:59+00:00
Accession:  0001104659-23-089437
Event type: earnings
Sentiment:  neutral
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Liquidia Q2 net loss widens to $23.5M; YUTREPIA patent litigation advances, L606 license acquired
--------------------------------------------------------------------------------

- Net loss $23.5M ($0.36/sh) vs $9.4M ($0.15/sh) in Q2 2022; revenue $4.8M, up from $3.9M.
- CAFC affirmed '066 patent invalid/non-infringed; one patent ('793) on appeal to CAFC, briefing Q4 2023.
- Filed amendment to add PH-ILD to YUTREPIA label; final approval gated by Tyvaso exclusivity ending March 31, 2024.
- Licensed L606 from Pharmosa for $10M upfront; Phase 3 PH-ILD study planned in 2024 after FDA meeting.
- Cash $88.2M as of June 30, 2023, vs $93.3M at Dec 31, 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819576/000110465923089437/0001104659-23-089437-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819576/000110465923089437/tm2323188d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-089437

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer